VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.6%
242M of 253M shares
Institutional holders
1,754
193 new, 110 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 93 sales
Net sold $158.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Capital World Investors | 25,695,015 | 10.10% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 21,881,203 | 8.50% | 13G (passive) | Dec 31, 2023 |
| Capital Research Global Investors | 21,139,169 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Vanguard Capital Management | 19,036,076 | 7.49% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VRTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Capital World Investors | 26,115,014 | 10.30% | $12.97B | +746,890 | 1.53% |
| BlackRock, Inc. | 24,109,373 | 9.51% | $11.98B | +139,856 | 0.18% |
| Capital Research Global Investors | 19,490,637 | 7.69% | $9.68B | −1,635,327 | 1.35% |
| Vanguard Capital Management LLC | 16,580,713 | 6.54% | $8.24B | +67,903 | 0.18% |
| State Street Corp | 11,871,459 | 4.68% | $5.90B | +141,320 | 0.17% |
| Invesco Ltd. | 8,043,052 | 3.17% | $4.00B | +150,441 | 0.32% |
| JPMorgan Chase & Co | 6,517,600 | 2.57% | $3.26B | −515,556 | 0.18% |
| Geode Capital Management, LLC | 6,017,848 | 2.37% | $2.98B | −121,773 | 0.16% |
| Vanguard Portfolio Management LLC | 4,878,987 | 1.92% | $2.42B | −266,622 | 0.11% |
| Capital International Investors | 4,695,144 | 1.85% | $2.33B | −430,933 | 0.48% |
| Loomis Sayles & Co L P | 3,920,953 | 1.55% | $1.95B | −82,868 | 2.44% |
| Franklin Resources Inc | 3,347,253 | 1.32% | $1.66B | +2,796,121 | 0.36% |
| Wellington Management Group Llp | 3,247,658 | 1.28% | $1.61B | +35,069 | 0.28% |
| Morgan Stanley | 3,242,139 | 1.28% | $1.61B | +53,258 | 0.09% |
| UBS Asset Management Americas Inc | 3,086,683 | 1.22% | $1.53B | +29,287 | 0.28% |
| Bank Of America Corp /De/ | 3,039,178 | 1.20% | $1.51B | +160,995 | 0.10% |
| Alliancebernstein L.P. | 3,019,315 | 1.19% | $1.35B | −891,471 | 0.45% |
| Jennison Associates LLC | 2,998,530 | 1.18% | $1.49B | +258,471 | 0.89% |
| Norges Bank | 2,971,681 | 1.17% | $1.48B | New | 0.15% |
| Ameriprise Financial Inc | 2,604,822 | 1.03% | $1.29B | −28,659 | 0.26% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,754 | 242M | 95.6% | 193 / 706 | 618 / 110 | 17M | 10M |
| Q1 2026 | 1,697 | 238M | 93.8% | 155 / 681 | 600 / 105 | 37M | 17M |
| Q4 2025 | 1,669 | 242M | 95.6% | 273 / 619 | 568 / 99 | 23M | 19M |
| Q3 2025 | 1,521 | 239M | 94.2% | 143 / 556 | 614 / 157 | 20M | 23M |
| Q2 2025 | 1,562 | 242M | 95.7% | 121 / 617 | 610 / 149 | 16M | 14M |
| Q1 2025 | 1,615 | 241M | 95.0% | 209 / 637 | 578 / 128 | 16M | 11M |
| Q4 2024 | 1,560 | 237M | 93.5% | 200 / 555 | 616 / 155 | 18M | 23M |
| Q3 2024 | 1,548 | 242M | 95.5% | 123 / 626 | 584 / 106 | 32M | 11M |
| Q2 2024 | 1,549 | 242M | 95.5% | 173 / 662 | 517 / 93 | 14M | 19M |
| Q1 2024 | 1,495 | 248M | 98.0% | 174 / 609 | 518 / 97 | 19M | 15M |
| Q4 2023 | 1,440 | 245M | 96.6% | 244 / 560 | 480 / 61 | 22M | 13M |
| Q3 2023 | 1,279 | 236M | 93.2% | 84 / 534 | 460 / 78 | 8M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VRTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Growth Fund of America | 12,497,307 | 4.93% | $5.59B | 1.55% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,058,128 | 3.18% | $4.00B | 0.17% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 6,576,510 | 2.59% | $3.27B | 0.20% | Jun 30, 2026 |
| Investment Co of America | 6,269,142 | 2.47% | $3.11B | 1.69% | Jun 30, 2026 |
| American Balanced Fund | 5,558,357 | 2.19% | $2.76B | 0.96% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 5,387,574 | 2.13% | $2.68B | 0.55% | Jun 30, 2026 |
| AMCAP Fund | 4,651,898 | 1.84% | $2.08B | 2.14% | May 31, 2026 |
| iShares Core S&P 500 ETF | 3,491,802 | 1.38% | $1.73B | 0.20% | Jun 30, 2026 |
| New Perspective Fund | 3,366,011 | 1.33% | $1.67B | 0.98% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 3,250,444 | 1.28% | $1.45B | 0.17% | May 31, 2026 |
| Vanguard Growth Index Fund | 2,784,526 | 1.10% | $1.38B | 0.36% | Jun 30, 2026 |
| Capital World Growth & Income Fund | 2,338,257 | 0.92% | $1.05B | 0.66% | May 31, 2026 |
| Washington Mutual Investors Fund | 1,975,814 | 0.78% | $942.66M | 0.43% | Jul 31, 2026 |
| Vanguard Health Care Fund | 1,890,142 | 0.75% | $901.79M | 2.36% | Jul 31, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,793,091 | 0.71% | $890.68M | 2.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Reshma Kewalramani | CEO & President, Director | 105,998 | 0.04% | Mar 3, 2026 |
| Jeffrey M. Leiden | Executive Chairman, Director | 35,237 | 0.01% | Feb 26, 2026 |
| Grunsven Jasper van | EVP, CP and NPPO | 8,682 | 0.00% | Sep 10, 2026 |
| Kristen Ambrose | SVP & Chief Accounting Officer | 11,624 | 0.00% | Sep 1, 2026 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 74,031 | 0.03% | Jul 23, 2026 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 53,572 | 0.02% | Jul 23, 2026 |
| Duncan McKechnie | EVP, Chief Commercial Officer | 11,001 | 0.00% | Jul 7, 2026 |
| Joy Liu | EVP and Chief Legal Officer | 19,131 | 0.01% | Jul 6, 2026 |
| Carmen Bozic | EVP and CMO | 15,337 | 0.01% | Jun 30, 2026 |
| Mark E. Bunnage | EVP, Chief Scientific Officer | 7,284 | 0.00% | May 19, 2026 |
| Charles F. Wagner Jr | EVP, CO & FO | 47,042 | 0.02% | Feb 26, 2026 |
| Jonathan Biller | EVP and Chief Legal Officer | 13,659 | 0.01% | Feb 26, 2026 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | 18,432 | 0.01% | Feb 26, 2026 |
| David Altshuler | EVP, Chief Scientific Officer | 34,477 | 0.01% | Jan 26, 2026 |
| Stuart A. Arbuckle | EVP, COO | 63,508 | 0.03% | Jul 2, 2025 |
| Bruce I. Sachs | Director | 39,000 | 0.02% | Aug 31, 2026 |
| Alan M. Garber | Director | 7,344 | 0.00% | Jul 17, 2026 |
| Jennifer Schneider | Director | 2,190 | 0.00% | May 5, 2026 |
| Michel Lagarde | Director | 1,132 | 0.00% | May 5, 2026 |
| Nancy Thornberry | Director | 2,109 | 0.00% | May 5, 2026 |
| Diana McKenzie | Director | 3,381 | 0.00% | May 5, 2026 |
| Lloyd Carney | Director | 6,315 | 0.00% | May 5, 2026 |
| Sangeeta N. Bhatia | Director | 4,924 | 0.00% | May 5, 2026 |
| Suketu Upadhyay | Director | 1,558 | 0.00% | May 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Grunsven Jasper van EVP, CP and NPPO | Sep 8, 2026 | Award | +8,682 | – | – | 8,682 |
| Kristen Ambrose SVP & Chief Accounting Officer | Aug 28, 2026 | Award | +5,000 | – | – | 11,624 |
| Bruce I. Sachs Director | Aug 27, 2026 | Gift | −6,000 | – | – | 39,000 |
| Amit Sachdev EVP Chief Patient & Ext Af Off | Jul 21, 2026 | Award | +8,251 | – | – | 66,512 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Jul 21, 2026 | Award | +8,251 | – | – | 53,572 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Jul 2, 2026 | Sale(10b5-1 plan) | −1,500 | $524.99 | $787.49K | 45,321 |
| Duncan McKechnie EVP, Chief Commercial Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −1,541 | $519.00 | $799.78K | 11,001 |
| Joy Liu EVP and Chief Legal Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −828 | $502.71 | $416.24K | 19,131 |
| Carmen Bozic EVP and CMO | Jun 26, 2026 | Sale(10b5-1 plan) | −596 | $482.50 | $287.57K | 15,337 |
| Carmen Bozic EVP and CMO | Jun 18, 2026 | Sale(10b5-1 plan) | −1,020 | $462.17 | $471.41K | 15,933 |
| Carmen Bozic EVP and CMO | Jun 15, 2026 | Sale(10b5-1 plan) | −4,062 | $450.00 | $1.83M | 16,953 |
| Carmen Bozic EVP and CMO | Jun 5, 2026 | Sale(10b5-1 plan) | −1,745 | $450.00 | $785.25K | 21,015 |
| Joy Liu EVP and Chief Legal Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −828 | $439.91 | $364.25K | 19,959 |
| Carmen Bozic EVP and CMO | May 29, 2026 | Sale(10b5-1 plan) | −1,974 | $450.00 | $888.30K | 22,760 |
| Carmen Bozic EVP and CMO | May 15, 2026 | Sale(10b5-1 plan) | −1,354 | $453.45 | $613.97K | 24,734 |
| Mark E. Bunnage EVP, Chief Scientific Officer | May 15, 2026 | Sale(10b5-1 plan) | −33 | $453.45 | $14.96K | 7,284 |
| Carmen Bozic EVP and CMO | May 12, 2026 | Sale(10b5-1 plan) | −6,988 | $450.00 | $3.14M | 26,088 |
| Sangeeta N. Bhatia Director | May 4, 2026 | Sale(10b5-1 plan) | −318 | $423.73 | $134.75K | 4,924 |
| Nancy Thornberry Director | May 1, 2026 | Returned to company | −398 | – | – | 2,109 |
| Nancy Thornberry Director | May 1, 2026 | Award | +472 | – | – | 2,507 |
| Sangeeta N. Bhatia Director | May 1, 2026 | Award | +943 | – | – | 5,242 |
| Joy Liu EVP and Chief Legal Officer | May 1, 2026 | Sale(10b5-1 plan) | −1,104 | $425.02 | $469.22K | 20,729 |
| Alan M. Garber Director | May 1, 2026 | Award | +472 | – | – | 7,344 |
| Jennifer Schneider Director | May 1, 2026 | Award | +472 | – | – | 2,190 |
| Jennifer Schneider Director | May 1, 2026 | Returned to company | −796 | – | – | 1,394 |
| Suketu Upadhyay Director | May 1, 2026 | Returned to company | −796 | – | – | 1,558 |
| Diana McKenzie Director | May 1, 2026 | Award | +943 | – | – | 3,174 |
| Diana McKenzie Director | May 1, 2026 | Returned to company | −796 | – | – | 2,378 |
| Joy Liu EVP and Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −978 | $449.17 | $439.29K | 21,833 |
| Carmen Bozic EVP and CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −2,329 | $450.95 | $1.05M | 33,076 |
| Carmen Bozic EVP and CMO | Mar 13, 2026 | Sale(10b5-1 plan) | −2,329 | $481.79 | $1.12M | 35,405 |
| Duncan McKechnie EVP, Chief Commercial Officer | Mar 11, 2026 | Sale(10b5-1 plan) | −2,633 | $498.42 | $1.31M | 12,489 |
| Duncan McKechnie EVP, Chief Commercial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,437 | $475.30 | $1.16M | 15,122 |
| Joy Liu EVP and Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −892 | $495.96 | $442.40K | 22,811 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −15,580 | $495.38 | $7.72M | 105,998 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −3,498 | $494.33 | $1.73M | 121,578 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,520 | $493.29 | $1.24M | 125,076 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −949 | $491.30 | $466.24K | 127,596 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,725 | $490.54 | $1.34M | 128,545 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −5,995 | $496.16 | $2.97M | 100,003 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −1,725 | $496.95 | $857.24K | 98,278 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −460 | $489.32 | $225.09K | 131,270 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −400 | $479.75 | $191.90K | 137,878 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −120 | $481.50 | $57.78K | 137,758 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −240 | $482.84 | $115.88K | 137,518 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,510 | $487.13 | $1.22M | 135,008 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −3,278 | $488.27 | $1.60M | 131,730 |
| Carmen Bozic EVP and CMO | Feb 27, 2026 | Sale(10b5-1 plan) | −2,329 | $480.31 | $1.12M | 37,734 |
| Kristen Ambrose SVP & Chief Accounting Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −357 | $483.36 | $172.56K | 6,624 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Feb 25, 2026 | Sale(10b5-1 plan) | −260 | $486.35 | $126.45K | 46,763 |
| Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | Feb 25, 2026 | Sale(10b5-1 plan) | −668 | $486.35 | $324.88K | 18,432 |
| Jonathan Biller EVP and Chief Legal Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −945 | $486.35 | $459.60K | 13,659 |
| Mark E. Bunnage EVP, Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −620 | $486.35 | $301.54K | 7,284 |
| Duncan McKechnie EVP, Chief Commercial Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −2,500 | $486.35 | $1.22M | 19,969 |
| Duncan McKechnie EVP, Chief Commercial Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −2,410 | $489.00 | $1.18M | 17,559 |
| Kristen Ambrose SVP & Chief Accounting Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −223 | $486.35 | $108.46K | 6,981 |
| Amit Sachdev EVP Chief Patient & Ext Af Off | Feb 25, 2026 | Sale(10b5-1 plan) | −1,846 | $486.35 | $897.80K | 55,570 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Feb 24, 2026 | Tax withholding | −1,627 | $485.11 | $789.27K | 47,023 |
| Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | Feb 24, 2026 | Tax withholding | −1,627 | $485.11 | $789.27K | 19,100 |
| Jonathan Biller EVP and Chief Legal Officer | Feb 24, 2026 | Tax withholding | −1,144 | $485.11 | $554.97K | 14,604 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| I. Sachs Bruce Director | Aug 27, 2026 | 1,210 | $662.54K | Aug 27, 2026 | Acquired as a gift |
| Ourania Tatsis Officer | Jul 2, 2026 | 1,500 | $787.49K | Jul 2, 2026 | Restricted Stock Vesting |
| Duncan McKechnie Officer | Jul 2, 2026 | 1,541 | $799.78K | Jul 2, 2026 | Restricted Stock Vesting |
| Joy Liu Officer | Jul 1, 2026 | 828 | $416.24K | Jul 1, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 26, 2026 | 596 | $287.57K | Jun 26, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 18, 2026 | 1,020 | $471.41K | Jun 18, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 15, 2026 | 4,062 | $1.83M | Jun 15, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 5, 2026 | 1,745 | $785.25K | Jun 5, 2026 | Restricted Stock Vesting |
| Joy Liu Officer | Jun 1, 2026 | 828 | $364.25K | Jun 1, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | May 29, 2026 | 1,974 | $888.30K | May 29, 2026 | Restricted Stock Vesting |
| Mark E. Bunnage Officer | May 15, 2026 | 33 | $14.96K | May 15, 2026 | ESPP Purchase |
| Carmen Bozic Officer | May 15, 2026 | 1,354 | $613.97K | May 15, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | May 12, 2026 | 6,988 | $3.14M | May 12, 2026 | Restricted Stock Vesting |
| Jonathan Biller Officer | May 6, 2026 | 5,193 | $2.20M | May 6, 2026 | Restricted Stock Vesting |
| Sangeeta N. Bhatia Director | May 4, 2026 | 318 | $134.75K | May 4, 2026 | Restricted Stock Vesting |